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Summary Obstructive sleep apnea syndrome (OSAS) has been shown to be associated
to upper airway inflammation. The object of the present study was to establish the
presence of bronchial inflammation in OSAS subjects.
In 16 subjects affected by OSAS, and in 14 healthy volunteers, airway inflammation
was detected by the cellular analysis of the induced sputum.
OSAS patients, as compared to control subjects, showed a higher percentage of
neutrophils (66.7718.9 vs. 25.8715.6) (Po0:001) and a lower percentage of
macrophages (29.4718.4 vs. 70.8715.3) (Po0:001). The percentage of eosinophils
and lymphocytes were not significantly different in the two groups.
OSAS subjects show bronchial inflammation characterized by a significant increase
in neutrophils.






Obstructive sleep apnea syndrome (OSAS) is char-
acterized by repetitive episodes of upper airway
occlusion during sleep. Nasal inflammation, uvula
mucosal congestion and airway hyperresponsive-
ness has been shown to be associated with OSAS.1–3
Upper airways and in particular nasal inflammation
are believed to be the consequence of the
mechanical stress associated to the obstruction to
the air passage characteristic of the disease. To the
contrary, little or no data is available in literature
on the presence of bronchial inflammation in OSAS.
Olopade et al.4 have shown an increase in exhaled
pentane, a marker of airway inflammation, in OSAS
subjects in the morning suggesting the develop-
ment of airway inflammation during sleep. More
recently, Carpagnano et al.5 have shown in the
breath condensate of OSAS patients an increase of
two markers of inflammation and oxidative stress,
IL6 and 8-isoprostane, suggesting that inflammation
and oxidative stress are characteristic in the
airways of OSAS patients. However, although these
studies provide evidence about the presence of
biomarkers of bronchial inflammation, no data on
the inflammatory cell profile are available. We,
therefore, investigated the bronchial inflammatory
cell profile in OSAS patients by utilizing the analysis
of the induced sputum.
Methods
Subjects
Sixteen consecutive patients (14 males, age 60710
years, BMI 3779) affected by OSAS and 14 age-
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matched healthy subjects (9 males, age 5674
years, BMI 2171) chosen as the control group were
enrolled. All subjects had no history of asthma,
chronic bronchitis, wheezing or allergies or other
systemic diseases that might contribute to sleep
disorders, were no smokers, and free from steroids
or other anti-inflammatory drugs. None of the
subjects were using CPAP therapy. Informed con-
sent was obtained from all subjects and Institution
Ethic Committee approved the study.
All subjects underwent to the Berlin Question-
naire,6 a pulmonary function test, a nocturnal
oxymetry and induced sputum. Because all healthy
subjects presented no risk of OSAS at the Berlin
Questionnaire and no alterations of nocturnal
oxymetry, only the OSAS subjects underwent to a
polysomnography.
Nocturnal oxymetry
Nocturnal haemoglobin oxygen saturation was
evaluated by finger pulse oxymetry (Minolta, Pulsox
DP 8, Japan). A pattern of oxymetry tracing
positive for OSAS was defined as a cyclical oxygen
desaturation defined as a drop in oxygen saturation
X4%.
Pulmonary function testing
Pulmonary function tests (Vmax 6200 Autobox,
SensorMedics, Yorba Linda, CA) were performed
prior to entry into the study in order to exclude an
obstructive lung disease defined as a FEV1%pred of
less than 80 and a FEV1/FVC ratio of less than 0.7.
Polysomnography
The OSAS subjects were evaluated in the sleep
laboratory with an overnight polysomnography
(Sleep Lab 1000p, Aequitron Medical, MN, USA).
Sleep disordered breathing was quantified by RDI
(Respiratory Disturbance Index), as the ratio of the
number of respiratory events (apneasþ hypopneas)
per hour of sleep. Apneas were defined as the total
cessation of airflow for at least 10 s in duration.
Hypopneas were defined as a 50% or greater
reduction in tidal volume from baseline value
lasting at least 10 s. An RDI larger than 10 was
considered diagnostic of OSAS.
Induced sputum technique
Inhalation procedure
After baseline FEV1 and FVC measurements, salbu-
tamol was given by inhalation (200 mg by a
metered-dose inhaler) and subjects inhaled hyper-
tonic (4.5%) saline nebulized for three periods of
5min each. An ultrasonic nebulizer (De Vilbiss 65,
De Vilbiss Corporation, Somerset, PA, USA) neb-
ulized saline solutions.
Sputum processing
The collected sputum samples were examined
within 2 h. Selected portions of the sputum sample
originating from the lower respiratory tract were
analyzed. Dithiothreitol (DTT, Sputolysin, Calbio-
chem Corp, San Diego, CA, USA), freshly prepared
in a dilution of one in 10 with distilled water, was
added in a volume (in ml) equal to 4 times the
weight of the sputum portion (in mg). Selected
sputum was placed in a shaking water bath at 371C
for 20min and homogenized. It was further diluted
with Phosphate Buffered Saline (PBS) in a volume
equal to the sputum plus DTT. The suspension was
filtered through gauze to remove mucus and was
centrifuged at 1000 rpm for 5min. The cell pellet
was resuspended in a volume of PBS equal to that of
the sputum plus DTT and PBS as above. Total cell
count (TCC) and viability (Trypan blue exclusion
method) were determined using a Burkers chamber
haemocytometer. The cell suspension was placed in
a Shandon 3 cytocentrifuge (Shandon Southern
Instruments, Sewickley, PA, USA) and cytospins
were prepared at 450 rpm for 6min. Cytospin slides
were fixed by methanol and stained by May
Grunwald Giemsa for an overall differential cell
count on 500 nucleated nonsquamous cells. Only
samples with cell viability450% and squamous cell
contamination o20% were considered adequate.
Statistical analysis
Mann–Withney U-test was used to analyze the
differences between the two groups. Spearman
Rank test was used to analyze the effect of BMI on
the % cells. Values are reported as mean7SD.
Significance was defined as a P value o0.05.
Results
All subjects had a normal pulmonary function test;
FVC%pred was 109715 vs. 10279, and FEV1%pred
was 109715 vs. 103711 in the control and OSAS
group respectively. BMI was significantly higher in
the OSAS subjects (Po0:001). RDI in the OSAS group
was 44725 (range 13–95). Figure 1 shows the
cellular profile of the induced sputum in the control
and OSAS group. A significantly higher percentage
of neutrophils (66.7718.9 vs. 25.8715.6)
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(Po0:001), and a significantly lower percentage of
macrophages (29.4718.4 vs. 70.8715.3)
(Po0:001) were detected in the induced sputum
of the OSAS group as compared to the control
group. The relative percentage of eosinophils
(1.171.4 vs. 0.870.8), lymphocytes (1.873.2 vs.
0.871.0) and epithelial cells (1.172.3 vs.
1.871.7) in the OSAS and control group, respec-
tively, were not statistically different. The relative
percentage of lymphocytes was somewhat higher in
the OSAS population for the presence of two
subjects with a 10% and 8% of lymphocytes. There
was no significant correlation between BMI and any
of the cellular components of the induced sputum
within the OSAS group (Fig. 2).
Discussion
In the present study we have shown that patients
affected by OSAS present a variable degree of
neutrophilic bronchial inflammation.
There is evidence in the literature that patients
affected by OSAS develop upper airways inflamma-
tion. Rubinstein et al.1 have shown in the nasal
mucosa of patients affected by OSAS, an increase in
the percentage of PMN (Polymorphonuclear Leuko-
cyte), as well as an increase in other mediators of
inflammation such as bradykinin and VIP (Vasoac-
tive Intestinal Peptide), suggesting a pathogenetic
role of the nasal inflammation in the upper airway
obstruction characteristic of the OSAS. In addition,
Sekosan et al.2 have shown, in OSAS patients, that
the uvula is thicker than normal and that in the
lamina propria there is an increase in the number of
leukocytes suggesting, again, that soft palate
inflammation contributes to the upper airway
occlusion observed during sleep. The reports on
the presence of bronchial inflammation in the OSAS
patients are less conclusive. Even though markers
of airway inflammation and oxidative stress have
been shown in previous studies4,5 in OSAS patients,
the technique used to sample the markers could
not differentiate the upper airways from the
bronchial compartment.
In the present study in order to investigate the
bronchial inflammatory profile of the OSAS popula-
tion we have utilized the analysis of induced
sputum, a standardized and widely used techni-
que.7 The OSAS patients showed a variable degree
of neutrophilic airway inflammation. Despite the
study was on a limited number of subjects, and a
larger population study is desiderable, the differ-
ence in the percentage of neutrophils and macro-
phages in the sputum between the two groups was
large enough to make the statistic highly signifi-
cant. A possible bias of this study is the lack of
polysomnography in the control group. However,
we feel confident that the nocturnal oxymetry in
association with the Berlin Questionnaire were able
to screen out the OSAS cases by the control group.
There are a number of reasons why bronchial
inflammation may be present in OSAS. The mechan-
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Figure 1 Induced sputum cellular profile in the OSAS
group (empty triangles) and in the control group (filled


































Figure 2 Percentage of neutrophils and macrophages vs.
BMI in the OSAS subjects. The correlation between the
two cellular components and BMI was not significant
(neutrophils vs. BMI: r ¼ 0:14; macrophages vs. BMI:
r ¼ 0:19).
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system by the snoring, proposed as responsible of
the upper airway inflammation observed in the
OSAS population, may also be responsible of the
bronchial inflammation. We speculate that the
pressure gradient caused by the intermittent
obstruction is likely transmitted to all the respira-
tory system. As theorized for the uvula and nasal
inflammation present in patients with OSAS,8 the
snoring-related mechanical trauma may not be the
sole mechanism underlying the bronchial inflam-
mation we have found in the present study.
Bronchial inflammation may be caused by the
activation of the neural receptors by proinflamma-
tory neuropeptides and peptides causing bronchial
edema. Hypoxemia and obesity, alone and in
combination, are also theoretical potential causes
of bronchial inflammation and their independent
role merit further investigation. In the present
study the potential effect of obesity on bronchial
inflammation has not been studied. To our knowl-
edge, no data are available on a positive correla-
tion between obesity and bronchial inflammation.
Carpagnano et al.5 did not find a clear correlation
between obesity alone and biomarkers of inflam-
mation in the breath condensate. In addition, in the
present study no correlation was found when BMI
was plotted vs. % of neutrophils.
In conclusion obese patients affected by OSAS
display neutrophilic airway inflammation. Airway
inflammation may be the consequence of the
mechanical stress on the mucosa because of the
intermittent obstruction of the upper airways
typical of the OSAS. Bronchial inflammation, how-
ever induced, may contribute to the pathogenesis
of the disease by determining further reduction of
the airway caliber. Further studies are necessary in
order to assess the effect of therapeutic interven-
tions such as the CPAP and anti-inflammatory
agents on the degree of the OSAS-induced bronchial
inflammation.
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